Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 2:58 AM
Ignite Modification Date:
2025-12-26 @ 1:39 AM
NCT ID:
NCT01136733
Group ID:
EG004
Title:
Phase 2 (Arm A): 18 mg Lenvatinib Plus 5 mg Everolimus
Description:
Oral lenvatinib (18mg) and everolimus (5 mg) were taken once daily in the morning (consistently with or without food) with water, in continuous 28-day (4-week) cycles. Treatment cycles began with the first dose of study drug in Cycle 1 and continued in 28-day (4-week) consecutive cycles until completion of the off-treatment assessments (within 30 days after the last study treatment administration). Study drugs were administered at the clinic for the first dose and on the pharmacokinetic (PK) sampling days.
Deaths Number Affected:
43
Deaths Number At Risk:
None
Serious Number Affected:
30
Serious Number At Risk:
51
Other Number Affected:
51
Other Number At Risk:
51
Study:
NCT01136733
Results Section:
NCT01136733
Adverse Events Module:
NCT01136733